Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Milsom

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
European Urology|October 20, 2006
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyDebra E Irwin, Ian Milsom, Steinar Hunskaar, et al.
The Journal of Sexual Medicine|December 19, 2008
Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in menDebra E Irwin, Ian Milsom, Kate Reilly, et al.
International Journal of Cancer|December 13, 2012
Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trialGudrun Broberg, Junmei Miao Jonasson, Joy Ellis, et al.
European Urology|November 28, 2012
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trialVik Khullar, Gerard Amarenco, Javier C Angulo, et al.
American Journal of Obstetrics and Gynecology|October 24, 2017
Predicting risk of pelvic floor disorders 12 and 20 years after deliveryJ Eric Jelovsek, Kevin Chagin, Maria Gyhagen, et al.
Contraception|December 13, 2006
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenoneHans-Joachim Ahrendt, Israel Nisand, Carlo Bastianelli, et al.
BJU International|March 24, 2009
The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTSChris C Sexton, Karin S Coyne, Zoe S Kopp, et al.
Neurourology and Urodynamics|March 16, 2012
Can we prevent incontinence? ICI-RS 2011Karl-Dietrich Sievert, Bastian Amend, Patricia A Toomey, et al.
BJU International|July 12, 2008
A review of adherence to drug therapy in patients with overactive bladderRamandeep K Basra, Adrian Wagg, Christopher Chapple, et al.
European Urology Focus|October 19, 2019
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom ComplexChristopher R Chapple, Emma Mironska, Adrian Wagg, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
European Urology|October 20, 2006
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC studyDebra E Irwin, Ian Milsom, Steinar Hunskaar, et al.
The Journal of Sexual Medicine|December 19, 2008
Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in menDebra E Irwin, Ian Milsom, Kate Reilly, et al.
International Journal of Cancer|December 13, 2012
Increasing participation in cervical cancer screening: telephone contact with long-term non-attendees in Sweden. Results from RACOMIP, a randomized controlled trialGudrun Broberg, Junmei Miao Jonasson, Joy Ellis, et al.
European Urology|November 28, 2012
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trialVik Khullar, Gerard Amarenco, Javier C Angulo, et al.
American Journal of Obstetrics and Gynecology|October 24, 2017
Predicting risk of pelvic floor disorders 12 and 20 years after deliveryJ Eric Jelovsek, Kevin Chagin, Maria Gyhagen, et al.
Contraception|December 13, 2006
Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenoneHans-Joachim Ahrendt, Israel Nisand, Carlo Bastianelli, et al.
BJU International|March 24, 2009
The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTSChris C Sexton, Karin S Coyne, Zoe S Kopp, et al.
Neurourology and Urodynamics|March 16, 2012
Can we prevent incontinence? ICI-RS 2011Karl-Dietrich Sievert, Bastian Amend, Patricia A Toomey, et al.
BJU International|July 12, 2008
A review of adherence to drug therapy in patients with overactive bladderRamandeep K Basra, Adrian Wagg, Christopher Chapple, et al.
European Urology Focus|October 19, 2019
Multicriteria Decision Analysis Applied to the Clinical Use of Pharmacotherapy for Overactive Bladder Symptom ComplexChristopher R Chapple, Emma Mironska, Adrian Wagg, et al.
Pageof 14